Gesamtlänge aller Episoden: 11 days 12 hours 51 minutes
Step-by-Step: Setting a Course for Long-Term Control of Type 2 Diabetes With GLP-1 RAs
Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC
Biologics and Beyond in Atopic Dermatitis: Emerging Targets and How They Work
"Improving Outcomes in Early-Stage EGFR-Mutant NSCLC: What Pathologists Can Do"
Why Combination Therapies and Why Now? The Rationale and Role of GLP-1 RAs and Insulin
Reassessing What’s Possible in Early-Stage EGFR-mutant NSCLC: Insights from the Latest Data
Strategies to Individualize Antidepressant Adjunct Therapy in MDD to Achieve Best Patient Outcomes
Best Practices in Early-Stage EGFR-Mutant NSCLC: What Surgeons Need to Know
Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy
Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer